Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM156 in advanced solid tumors and lymphoma
NCT03272256Phase 1Completed
- Sponsor
- ImmunoMet Therapeutics
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lixumistat in solid tumor (advanced stage) and lymphoma, sponsored by ImmunoMet Therapeutics. Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Oct 2017; status: completed.
02
Drugs
lixumistat
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT03272256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272256.